The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 28, 2023

Filed:

Jun. 04, 2021
Applicant:

Xilio Development, Inc., Waltham, MA (US);

Inventors:

Margaret Karow, Santa Rosa Valley, CA (US);

Deborah Moore Lai, Beverly, MA (US);

Dheeraj Singh Tomar, Dorchester, MA (US);

Parker Johnson, Allston, MA (US);

Raphael Rozenfeld, Newton, MA (US);

Ronan O'Hagan, Waltham, MA (US);

Huawei Qiu, Westborough, MA (US);

Assignee:

Xilio Development, Inc., Waltham, MA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/00 (2006.01); C07K 14/55 (2006.01); A61P 35/00 (2006.01); C07K 14/54 (2006.01);
U.S. Cl.
CPC ...
C07K 14/55 (2013.01); A61P 35/00 (2018.01); C07K 14/5443 (2013.01); A61K 38/00 (2013.01); C07K 2317/52 (2013.01); C07K 2317/94 (2013.01); C07K 2319/30 (2013.01);
Abstract

Provided herein are cytokines or functional fragments thereof that, in some embodiments, are engineered to be masked by a masking moiety at one or more receptor binding site(s) of the cytokine or functional fragment thereof. In some embodiments, the cytokines are engineered to be activatable by a protease at a target site, such as in a tumor microenvironment, by including a proteolytically cleavable linker. In some embodiments, the proteolytically cleavable linker links the cytokine to the masking moiety, links the cytokine to a half-life extension domain, and/or links the masking moiety to a half-life extension domain. The masking moiety blocks, occludes, inhibits (e.g., decreases) or otherwise prevents (e.g., masks) the activity or binding of the cytokine to its cognate receptor or protein. Upon proteolytic cleavage of the cleavable linker at the target site, the cytokine becomes activated, which renders it capable of binding to its cognate receptor or protein with increased affinity.


Find Patent Forward Citations

Loading…